Literature DB >> 27393458

Blockade of receptor for advanced glycation end products protects against systolic overload-induced heart failure after transverse aortic constriction in mice.

Yu Liu1, Manli Yu2, Zhigang Zhang2, Yunhua Yu2, Qi Chen2, Wei Zhang2, Xianxian Zhao3.   

Abstract

Heart failure is the consequence of sustained, abnormal neurohormonal and mechanical stress and remains a leading cause of death worldwide. The aim of this work was to identify whether blockade of receptor for advanced glycation end products (RAGE) protected against systolic overload-induced heart failure and investigate the possible underlying mechanism. It was found that RAGE mRNA and protein expression was up-regulated in cardiac tissues from mice subjected to pressure overload by transverse aortic constriction (TAC). Importantly, inhibition of RAGE by treatment with soluble RAGE (sRAGE) or FPS-ZM1 (a high-affinity RAGE-specific inhibitor) for 8 weeks attenuated cardiac remodeling (including cardiac hypertrophy and fibrosis), and dysfunction in mice exposed to TAC. Furthermore, treatment of TAC mice with sRAGE or FPS-ZM1 enhanced phosphorylation of AMPK and reduced phosphorylation of mTOR and protein expression of NFκB p65 in cardiac tissues. In addition, treatment of TAC mice with sRAGE or FPS-ZM1 abated oxidative stress, attenuated endoplasmic reticulum stress, and suppressed inflammation in cardiac tissues. These data demonstrated the benefits of blocking RAGE on the progression of systolic overload-induced heart failure in mice, which was possibly through modulating AMPK/mTOR and NFκB pathways.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AMPK/mTOR; Heart failure; NFκB; Receptor for advanced glycation end products; Transverse aortic constriction

Mesh:

Substances:

Year:  2016        PMID: 27393458     DOI: 10.1016/j.ejphar.2016.07.008

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  Molecular Characteristics of RAGE and Advances in Small-Molecule Inhibitors.

Authors:  Hyeon Jin Kim; Mi Suk Jeong; Se Bok Jang
Journal:  Int J Mol Sci       Date:  2021-06-27       Impact factor: 5.923

2.  Role of the Soluble Receptor for Advanced Glycation End Products (sRAGE) as a Prognostic Factor for Mortality in Hemodialysis and Peritoneal Dialysis Patients.

Authors:  Elena Dozio; Federico Ambrogi; Massimo de Cal; Elena Vianello; Claudio Ronco; Massimiliano M Corsi Romanelli
Journal:  Mediators Inflamm       Date:  2018-10-15       Impact factor: 4.711

3.  Inhibiting Receptor of Advanced Glycation End Products Attenuates Pressure Overload-Induced Cardiac Dysfunction by Preventing Excessive Autophagy.

Authors:  Wenbin Gao; Zheng Zhou; Birong Liang; Yusheng Huang; Zhongqi Yang; Yang Chen; Lu Zhang; Cui Yan; Jiajia Wang; Lu Lu; Zhaorui Wen; Shaoxiang Xian; Lingjun Wang
Journal:  Front Physiol       Date:  2018-09-24       Impact factor: 4.566

4.  Receptor for Advanced Glycation End Products Antagonism Blunts Kidney Damage in Transgenic Townes Sickle Mice.

Authors:  Emmanuelle Charrin; Camille Faes; Amandine Sotiaux; Sarah Skinner; Vincent Pialoux; Philippe Joly; Philippe Connes; Cyril Martin
Journal:  Front Physiol       Date:  2019-07-23       Impact factor: 4.566

Review 5.  Endothelial Dysfunction in Diabetes Is Aggravated by Glycated Lipoproteins; Novel Molecular Therapies.

Authors:  Laura Toma; Camelia Sorina Stancu; Anca Volumnia Sima
Journal:  Biomedicines       Date:  2020-12-27

Review 6.  Targeting RAGE to prevent SARS-CoV-2-mediated multiple organ failure: Hypotheses and perspectives.

Authors:  Sara Chiappalupi; Laura Salvadori; Aleksandra Vukasinovic; Rosario Donato; Guglielmo Sorci; Francesca Riuzzi
Journal:  Life Sci       Date:  2021-02-23       Impact factor: 5.037

7.  Elevated plasma sRAGE and IGFBP7 in heart failure decrease after heart transplantation in association with haemodynamics.

Authors:  Abdulla Ahmed; Salaheldin Ahmed; Mattias Arvidsson; Habib Bouzina; Jakob Lundgren; Göran Rådegran
Journal:  ESC Heart Fail       Date:  2020-06-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.